Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Clonixin→

Clonixin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
17737-65-4
Molecular formula
C13H11ClN2O2
Molecular weight
262.69 g/mol
Drug class
Non-steroidal anti-inflammatory drug (NSAID)nicotinic-acid derivative
Mechanism of action
The molecular mechanism is not fully characterised. As an NSAID, its pharmacology is presumed to include cyclo-oxygenase-mediated reduction of prostaglandin synthesis, contributing to analgesic and anti-inflammatory effects; this should be regarded as a class-based mechanism rather than a fully established compound-specific target profile.
Indications / reported uses
  • Management of pain and inflammation associated with chronic arthritic conditions and selected soft-tissue disorders in jurisdictions where clonixin is authorised

Sources: PubChem compound summary (includes MeSH class information and a note that molecular mechanism is incompletely investigated) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Clonixin Environmental Risk Assessment (ERA) (the Clonixin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.